Cardiology

Caissa Troutman, MD, shares 3 key strategies for managing hypertension in patients with obesity in primary care.

Caissa Troutman, MD, stresses the importance of building trust with patients through active listening and consistent, non-judgmental communication.

Caissa Troutman, member of the Obesity Medicine Association, emphasizes the importance of shared decision-making in overcoming barriers to managing hypertension and obesity.

Obesity medicine expert Caissa Troutman, MD, suggests using annual physicals as a "gateway" to identify patients with obesity with elevated blood pressure.

The Los Angeles wildfires continue nearly unabated despite heroic efforts by first responders. Wildfire smoke has both short- and long-term effects on health and habitat. Here's what to know, for you and your patients.

Caissa Troutman, MD, an obesity medicine and family medicine physician, emphasizes early treatment of obesity, along with HTN management, can improve patient outcomes.

Donna Ryan, MD, discusses the most significant clinical trials published this year in the field of obesity medicine.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

A woman in her early 50s presents with 6 hours of right sided pleuritic chest pain. What do the history and ECG suggest? What's yoru Dx?

The patient shows no signs of trauma but is a poor historian so no further details are available. Do her vitals or ECG provide any clues to a Dx?

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

Millions of US adults could benefit from semaglutide treatment for diabetes, obesity, and/or CV disease but insurance isn't guaranteed and the drug is costly.

Lp(a) is a genetically-driven and independent risk factor for CVD with no approved treatments. Lilly is advancing muvalaplin and has some good competition.

AHA 2024. Findings from the BPROAD trial help fill a gap left by similar studies on the ideal target SBP for adults with type 2 diabetes, said study authors.

Aprocitentan is the first-and-only dual endothelin receptor antagonist approved for the treatment of systemic hypertension.

AHA 2024. "...we did not anticipate this magnitude of increase in mortality," researchers said. They were also surprised by the population groups most affected.

AHA 2024. Study authors reported a 74% lower risk of death and an 84% lower risk of MI among participants taking either a GLP-1RA or an SGLT2i.

ObesityWeek 2024. Semaglutide 2.4 mg reduces rates of composite CV outcomes in high-risk patients without diabetes and now is shown to reduce inpatient care and length of stay.

Your daily dose of the clinical news you may have missed.

Novo Nordisk plans to file for regulatory approval this year of an expanded label for oral semaglutide, with an indication for reduction of MACE in high-risk adults with T2D.

Women remain underrepresented in heart disease research after decades of efforts to correct the balance, affecting trial data and women's cardiovascular care.

Prior SARS-CoV-2 infection was associated with a 2-fold increased risk for MACE for up to 3 years, even among people with no history of CVD, in a new analysis of UK Biobank data.

The use of visual imaging to detect atherosclerosis at its earliest stages and to quantify the burden enhances predictive value of traditional risk assessment tools.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

A continuous increase in ASCVD risk was seen with higher levels of lipoprotein(a) in the largest study to date of the relationship.

Your daily dose of the clinical news you may have missed.

How are you managing your patients with resistant or refractory hypertension? How do your strategies align with current guidelines? Try these 9 questions and find out.